Neuralstem, Inc., a biopharmaceutical company, focuses on the development and commercialization of treatments for central nervous system disease based on human neural stem cells and the use of small molecule compounds. Its stem cell technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons. Its products under development include NSI – 566, which has completed Phase I clinical trial for the proposed treatment of amyotrophic lateral sclerosis, as well as for chronic spinal cord injury and motor deficits due to ischemic stroke; and NSI – 189, a small molecule pharmaceutical compound, which is in Phase Ib clinical trial for the treatment of major depressive disorder. Neuralstem, Inc. was founded in 1996 and is headquartered in Rockville, Maryland.

Key Statistics